New study tracks psoriatic arthritis patients to predict joint damage

NCT ID NCT03768271

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 425 adults with recent psoriatic arthritis (PsA) for up to 10 years to see how many develop joint damage and what factors predict it. Researchers will use X-rays and other data to identify early signs of aggressive disease. The goal is to help doctors decide who needs stronger treatment sooner and to find new treatment targets.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 425 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2020

Expected to finish

Dec 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with peripheral psoriatic arthritis diagnosed at an early stage.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women or men aged from 18 to 65 inclusive * First episode of peripheral arthritis in the last 12 months, authenticated by a rheumatologist * Psoriasis diagnosed by a practitioner or family history of psoriatic arthritis (first-degree relative \[parent or sibling\] or second degree relative) * Arthritis most likely recognized as a psoriatic arthritis by a rheumatologist (diagnostic confidence score : ≥ 7 out of 10) * Signed informed consent form * Affiliation to a social security system Exclusion Criteria: * Formal diagnostic of inflammatory rheumatism other than psoriatic arthritis * Treatment or history of treatment with a biomedicine * Patient receiving csDMARDS (methotrexate, sulfasalazine, or leflunomide) or apremilast treatment over the past year for rheumatological symptoms * Oral steroids in the last 4 weeks, above 10 mg/d of prednisone or with modified dosage * intravenous or intra articular steroids in the last 4 weeks * IRM contraindication * Cognitive, mental or psychic disorders impeding protocol accomplishment * Difficulties with French language understanding * Patient under tutorship or curatorship * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cohort study are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cohort study Psoriatic arthritis (PSA) Recent peripheral arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

3 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New study tracks psoriatic arthritis patients to predict joint damage

What the study statuses mean